Serum Insulin-Like Growth Factor Axis and the Risk of Pancreatic Cancer: Systematic Review and Meta-Analysis.

Department of Hepatobiliary Surgery, The Affiliated Cancer Hospital& Institute of Guangzhou Medical University, Guangzhou 510095, China. medgongyf@126.com. Department of Ultrasound, the First People's Hospital of Yichang, China Three Gorges University, Yichang 443000, China. yczhangyb@126.com. Department of Hepatobiliary Surgery, The Affiliated Cancer Hospital& Institute of Guangzhou Medical University, Guangzhou 510095, China. medliaoyd@126.com. Department of Hepatobiliary Surgery, The Affiliated Cancer Hospital& Institute of Guangzhou Medical University, Guangzhou 510095, China. medtangyq@126.com. Department of Hepatobiliary Surgery, The Affiliated Cancer Hospital& Institute of Guangzhou Medical University, Guangzhou 510095, China. medmaic@126.com. Department of Hepatobiliary Surgery, The Affiliated Cancer Hospital& Institute of Guangzhou Medical University, Guangzhou 510095, China. medchentj@126.com. Department of Hepatobiliary Surgery, The Affiliated Cancer Hospital& Institute of Guangzhou Medical University, Guangzhou 510095, China. medtangh@126.com.

Nutrients. 2017;(4)
Full text from:

Abstract

OBJECTIVE To investigate the association between serum concentration of insulin-like growth factor (IGF) and the risk of pancreatic cancer (PaC). METHODS We identified eligible studies in Medline and EMBASE databases (no reference trials from 2014 to 2016) in addition to the reference lists of original studies and review articles on this topic. A summary of relative risks with 95% confidence intervals (CI) was calculated using a random-effects model. The heterogeneity between studies was assessed using Cochran Q and I² statistics. RESULTS Ten studies (seven nested case-control studies and three retrospective case-control studies) were selected as they met our inclusion criteria in this meta-analysis. All these studies were published between 1997 and 2013. The current data suggested that serum concentrations of IGF-I, IGF-II and insulin-like growth factor binding protein-3 (IGFBP-3)in addition to the IGF-I/IGFBP-3 ratio were not associated with an increased risk of PaC (Summary relative risks (SRRs) = 0.92, 95% CI: 0.67-1.16 for IGF-I; SRRs = 0.84, 95% CI: 0.54-1.15 for IGF-II; SRRs = 0.93, 95% CI: 0.69-1.17 for IGFBP-3; SRRs = 0.97, 95% CI: 0.71-1.23 for IGF-I/IGFBP-3 ratio). There was no publication bias in the present meta-analysis. CONCLUSION Serum concentrations of IGF-I, IGF-II, IGFBP-1 and IGFBP-3 as well as the IGF-I/IGFBP-3 ratio were not associated with increased risk of PaC.

Methodological quality

Publication Type : Meta-Analysis ; Review

Metadata